A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie glejak mózgu (glioblastoma) stopnia IV
- •Wznowienie choroby udokumentowane skanem MRI oraz badaniami obrazowymi
- •Ogólny stan zdrowia pacjenta na poziomie umożliwiającym uczestnictwo w badaniu
- •Dostępne próbki guza pobranego podczas operacji lub biopsji
- •Dla pacjentów nowo rozpoznanych: skan MRI wykonany w ciągu 21 dni przed włączeniem do badania
- •Dla pacjentów z nawrotami: poprzednie leczenie musiało zawierać radioterapię
✗ Disqualifies
- •Poprzednie leczenie glejaków, w tym chemioterapia lub radioterapia
- •Wcześniejsze leczenie immunoterapią lub innymi eksperymentalnymi metodami dla glejaków
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (63)
University of Alabama at Birmingham
Birmingham, United States
University of California, San Diego
La Jolla, United States
Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute
Los Angeles, United States
University of California, Los Angeles
Los Angeles, United States
St. Joseph Hospital
Orange, United States
University of California, San Francisco
San Francisco, United States
Stanford Cancer Center
Stanford, United States
University of Colorado Denver
Aurora, United States
Yale Cancer Center / Smilow Cancer Hospital*
New Haven, United States
Mayo Clinic Cancer Center
Jacksonville, United States
Sylvester Comprehensive Cancer Center*
Miami, United States
Moffitt Cancer Center
Tampa, United States
Piedmont Atlanta Hospital
Atlanta, United States
Winship Cancer Institute of Emory University
Atlanta, United States
LSU Health Sciences Center - New Orleans
New Orleans, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Henry Ford Health System
Detroit, United States
Allina Health Systems/Abbott Northwestern Hospital
Minneapolis, United States
Mayo Clinic Cancer Center - Rochester
Rochester, United States
University of Mississippi Medical Center
Jackson, United States
Washington University School of Medicine - Siteman Cancer Center
St Louis, United States
Perlmutter Cancer Center, NYU Langone Health
New York, United States
Icahn School of Medicine at Mount Sinai
New York, United States
Columbia University Medical Center
New York, United States
Memorial Sloan Kettering Cancer Center*
New York, United States
Duke University Medical Center
Durham, United States
Comprehensive Cancer Center of Wake Forest*
Winston-Salem, United States
University Hospitals Cleveland Medical Center*
Cleveland, United States
Cleveland Clinic
Cleveland, United States
Ohio State University Cancer Center
Columbus, United States
University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, United States
Allegheny General Hospital
Pittsburgh, United States
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, United States
Medical University of South Carolina - Hollings Cancer Center
Charleston, United States
Texas Oncology - Austin
Austin, United States
University of Texas Southwestern Medical Center
Dallas, United States
University of Texas - MD Anderson Cancer Center
Houston, United States
University of Utah - Huntsman Cancer Institute
Salt Lake City, United States
University of Virginia Health
Charlottesville, United States
University of Washington Medical Center
Seattle, United States
Froedtert Hospital/Medical College of Wisconsin
Milwaukee, United States
Northern Sydney Cancer Centre/Royal North Shore Hospital
St Leonards, Australia
Calvary Mater Newcastle
Waratah, Australia
Royal Brisbane and Women's Hospital
Herston, Australia
Flinders Medical Centre
Bedford Park, Australia
Austin Health
Heidelberg, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Sunnybrook Health Sciences Centre
Toronto, Canada
Princess Margaret Cancer Centre
Toronto, Canada
Montreal Neurological Institute and Hospital, McGill University
Montreal, Canada
Université de Sherbrooke
Sherbrooke, Canada
Centre Hospitalier Lyon Sud / Hôpital Neurologique P. Wertheimer
Bron, France
Hopital de la Timone
Marseille, France
Hopital Piti-Salpetriere
Paris, France
Uniklinik Koeln - Zentrum fuer Neurologie und Psychiatrie
Cologne, Germany
Dr. Senckenbergisches Institut für Neuroonkologie
Frankfurt, Germany
Universitätsklinik Heidelberg
Heidelberg, Germany
Universitaetsklinikum Heidelberg - Neurologische Klinik
Mannheim, Germany
Universitätsklinikum Regensburg
Regensburg, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Centre Hospitalier Universitaire Vaudois Lausanne
Lausanne, Switzerland
University Hospital Zurich
Zurich, Switzerland
Trial contact
Patient Information
Rachel Rosenstein-Sisson
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.